doi: 10.1007/s10787-022-00974-4 213 HuYZhangTChenJChengWChenJZhengZet al
through regulatory loopholes and are typically shipped from China, and Wall Street estimates suggest the market could develop into a multibillion-dollar business
From $129/mo Insurance Prior Authorization PA submission and advocacy for GLP-1 insurance approval
345,346 For example, gene therapy delivering NGF or its receptors has shown promise in enhancing nerve regeneration in diabetic models
So we chose the eye for a number of reasons, business-wise, science-wise, for the reasons you mentioned already, there are drugs on the market that its immune privileged, its got a relatively its a well-known safety profile, its certainly safer than delivering it through intravenous methods right now